Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-8001 in advanced MAGE-A1+ solid tumors
NCT05430555Phase 2Terminated
- Sponsor
- T-knife Therapeutics
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 5
01
Overview
A Phase 2 trial of TK-8001 in solid tumor, sponsored by T-knife Therapeutics. Started Jul 2022; status: terminated.
02
Drugs
TK-8001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05430555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430555.